TipRanks
Sarepta Therapeutics (MX:SRPT)
:SRPT
Mexico Market
SRPT
Sarepta Therapeutics
RESEARCH TOOLSreports

Sarepta Therapeutics (SRPT) Stock Forecast & Price Target

1 Followers
See the Price Targets and Ratings of:

SRPT Analyst Ratings

Hold
17Ratings
Hold
3 Buy
10 Hold
4 Sell
Based on 17 analysts giving stock ratings to
Sarepta
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

SRPT Stock 12 Month Forecast

Average Price Target

$406.60
▲(32.87% Upside)
Based on 17 Wall Street analysts offering 12 month price targets for Sarepta Therapeutics in the last 3 months. The average price target is $406.60 with a high forecast of $717.52 and a low forecast of $94.41. The average price target represents a 32.87% change from the last price of $306.00.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"93":"$93","718":"$718","249.25":"$249.3","405.5":"$405.5","561.75":"$561.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":717.52265874,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$717.52</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":406.59617328599995,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$406.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":94.41087615,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$94.41</span>\n  </div></div>","useHTML":true}}],"tickPositions":[93,249.25,405.5,561.75,718],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,350,378.2709737492308,406.5419474984615,434.8129212476923,463.08389499692305,491.35486874615384,519.6258424953846,547.8968162446154,576.1677899938461,604.438763743077,632.7097374923077,660.9807112415385,689.2516849907693,{"y":717.52265874,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,350,354.35355179123076,358.7071035824615,363.06065537369227,367.4142071649231,371.76775895615384,376.1213107473846,380.47486253861535,384.8284143298461,389.18196612107687,393.5355179123077,397.88906970353844,402.2426214947692,{"y":406.59617328599995,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,350,330.3392981653846,310.6785963307692,291.0178944961539,271.3571926615385,251.69649082692308,232.0357889923077,212.37508715769232,192.71438532307693,173.05368348846153,153.39298165384616,133.73227981923077,114.07157798461537,{"y":94.41087615,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":359.99,"date":1759276800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 34, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 15</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":450,"date":1761955200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":359,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":395,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 14</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":361,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":361,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 31, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 17</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":360,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":364,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":281,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":294,"date":1782864000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":294,"date":1785542400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":306,"date":1788220800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":350,"date":1790812800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$717.52Average Price Target$406.60Lowest Price Target$94.41
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on MX:SRPT
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
$94.41
Sell
-69.15%
Downside
Reiterated
10/30/26
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (NASDAQ: GILD), Bristol-Myers Squibb (NYSE: BMY) and Sarepta Therapeutics (NASDAQ: SRPT)
RBC Capital Analyst forecast on MX:SRPT
Brian Abrahams
RBC Capital
RBC Capital
$321
Hold
4.90%
Upside
Reiterated
10/27/26
RBC Capital Sticks to Its Hold Rating for Sarepta Therapeutics (SRPT)
Wedbush Analyst forecast on MX:SRPT
Yun Zhong
Wedbush
Wedbush
$660.88
Buy
115.97%
Upside
Reiterated
10/26/26
Sarepta: Buy Rating Reiterated, $35 Price Target Maintained on Emerging RNA Pipeline and Upcoming MAD Data Catalysts
TD Cowen Analyst forecast on MX:SRPT
Ritu Baral
TD Cowen
TD Cowen
$321
Hold
4.90%
Upside
Reiterated
10/21/26
Sarepta Therapeutics (SRPT) Receives a Rating Update from a Top Analyst
Piper Sandler Analyst forecast on MX:SRPT
Biren Amin
Piper Sandler
Piper Sandler
$377.64
Hold
23.41%
Upside
Reiterated
10/19/26
Analysts Offer Insights on Healthcare Companies: Definium Therapeutics (NASDAQ: DFTX), Sarepta Therapeutics (NASDAQ: SRPT) and BioNTech SE (NASDAQ: BNTX)
Leerink Partners Analyst forecast on MX:SRPT
Unknown Analyst
Leerink Partners
Not Ranked
Leerink Partners
$377.64
Hold
23.41%
Upside
Reiterated
10/15/26
Leerink Partners Reaffirms Their Hold Rating on Sarepta Therapeutics (SRPT)
Bank of America Securities Analyst forecast on MX:SRPT
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
$339.88
Sell
11.07%
Upside
Reiterated
10/09/26
Bank of America Securities Reaffirms Their Sell Rating on Sarepta Therapeutics (SRPT)
Wells Fargo Analyst forecast on MX:SRPT
Yanan Zhu
Wells Fargo
Wells Fargo
$717.52
Buy
134.48%
Upside
Reiterated
10/02/26
Wells Fargo Sticks to Their Buy Rating for Sarepta Therapeutics (SRPT)
J.P. Morgan Analyst forecast on MX:SRPT
Anupam Rama
J.P. Morgan
J.P. Morgan
$434.29→$377.64
Hold
23.41%
Upside
Assigned
09/30/26
Sarepta price target lowered to $20 from $23 at JPMorganSarepta price target lowered to $20 from $23 at JPMorgan
Needham Analyst forecast on MX:SRPT
Gil Blum
Needham
Needham
―
Sell
―
Reiterated
09/28/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Sarepta Therapeutics (NASDAQ: SRPT), BioNTech SE (NASDAQ: BNTX) and AgomAb Therapeutics NV ADR (NASDAQ: AGMB)
William Blair Analyst forecast on MX:SRPT
Lachlan Hanbury Brown
William Blair
William Blair
―
Hold
―
Reiterated
09/28/26
Elevidys ENDURE Study Shows Partial Risk Mitigation but Persistent Safety Concerns, Supporting Hold Rating
Citi Analyst forecast on MX:SRPT
Yigal Nochomovitz
Citi
Citi
$245.47
Sell
-19.78%
Downside
Reiterated
09/27/26
Sell Rating Reaffirmed on Sarepta as Regulatory Uncertainty Persists; $13 Price Target Maintained
Evercore ISI Analyst forecast on MX:SRPT
Gavin Clark-Gartner
Evercore ISI
Evercore ISI
$358.76
Hold
17.24%
Upside
Reiterated
08/10/26
Evercore ISI Reaffirms Their Hold Rating on Sarepta Therapeutics (SRPT)
Barclays Analyst forecast on MX:SRPT
Eliana Merle
Barclays
Barclays
$377.64
Hold
23.41%
Upside
Reiterated
08/07/26
Barclays Reaffirms Their Hold Rating on Sarepta Therapeutics (SRPT)
Morgan Stanley Analyst forecast on MX:SRPT
Michael Ulz
Morgan Stanley
Morgan Stanley
$472.05
Hold
54.27%
Upside
Assigned
08/06/26
Morgan Stanley Keeps Their Hold Rating on Sarepta Therapeutics (SRPT)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on MX:SRPT
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
$94.41
Sell
-69.15%
Downside
Reiterated
10/30/26
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (NASDAQ: GILD), Bristol-Myers Squibb (NYSE: BMY) and Sarepta Therapeutics (NASDAQ: SRPT)
RBC Capital Analyst forecast on MX:SRPT
Brian Abrahams
RBC Capital
RBC Capital
$321
Hold
4.90%
Upside
Reiterated
10/27/26
RBC Capital Sticks to Its Hold Rating for Sarepta Therapeutics (SRPT)
Wedbush Analyst forecast on MX:SRPT
Yun Zhong
Wedbush
Wedbush
$660.88
Buy
115.97%
Upside
Reiterated
10/26/26
Sarepta: Buy Rating Reiterated, $35 Price Target Maintained on Emerging RNA Pipeline and Upcoming MAD Data Catalysts
TD Cowen Analyst forecast on MX:SRPT
Ritu Baral
TD Cowen
TD Cowen
$321
Hold
4.90%
Upside
Reiterated
10/21/26
Sarepta Therapeutics (SRPT) Receives a Rating Update from a Top Analyst
Piper Sandler Analyst forecast on MX:SRPT
Biren Amin
Piper Sandler
Piper Sandler
$377.64
Hold
23.41%
Upside
Reiterated
10/19/26
Analysts Offer Insights on Healthcare Companies: Definium Therapeutics (NASDAQ: DFTX), Sarepta Therapeutics (NASDAQ: SRPT) and BioNTech SE (NASDAQ: BNTX)
Leerink Partners Analyst forecast on MX:SRPT
Unknown Analyst
Leerink Partners
Not Ranked
Leerink Partners
$377.64
Hold
23.41%
Upside
Reiterated
10/15/26
Leerink Partners Reaffirms Their Hold Rating on Sarepta Therapeutics (SRPT)
Bank of America Securities Analyst forecast on MX:SRPT
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
$339.88
Sell
11.07%
Upside
Reiterated
10/09/26
Bank of America Securities Reaffirms Their Sell Rating on Sarepta Therapeutics (SRPT)
Wells Fargo Analyst forecast on MX:SRPT
Yanan Zhu
Wells Fargo
Wells Fargo
$717.52
Buy
134.48%
Upside
Reiterated
10/02/26
Wells Fargo Sticks to Their Buy Rating for Sarepta Therapeutics (SRPT)
J.P. Morgan Analyst forecast on MX:SRPT
Anupam Rama
J.P. Morgan
J.P. Morgan
$434.29→$377.64
Hold
23.41%
Upside
Assigned
09/30/26
Sarepta price target lowered to $20 from $23 at JPMorganSarepta price target lowered to $20 from $23 at JPMorgan
Needham Analyst forecast on MX:SRPT
Gil Blum
Needham
Needham
―
Sell
―
Reiterated
09/28/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Sarepta Therapeutics (NASDAQ: SRPT), BioNTech SE (NASDAQ: BNTX) and AgomAb Therapeutics NV ADR (NASDAQ: AGMB)
William Blair Analyst forecast on MX:SRPT
Lachlan Hanbury Brown
William Blair
William Blair
―
Hold
―
Reiterated
09/28/26
Elevidys ENDURE Study Shows Partial Risk Mitigation but Persistent Safety Concerns, Supporting Hold Rating
Citi Analyst forecast on MX:SRPT
Yigal Nochomovitz
Citi
Citi
$245.47
Sell
-19.78%
Downside
Reiterated
09/27/26
Sell Rating Reaffirmed on Sarepta as Regulatory Uncertainty Persists; $13 Price Target Maintained
Evercore ISI Analyst forecast on MX:SRPT
Gavin Clark-Gartner
Evercore ISI
Evercore ISI
$358.76
Hold
17.24%
Upside
Reiterated
08/10/26
Evercore ISI Reaffirms Their Hold Rating on Sarepta Therapeutics (SRPT)
Barclays Analyst forecast on MX:SRPT
Eliana Merle
Barclays
Barclays
$377.64
Hold
23.41%
Upside
Reiterated
08/07/26
Barclays Reaffirms Their Hold Rating on Sarepta Therapeutics (SRPT)
Morgan Stanley Analyst forecast on MX:SRPT
Michael Ulz
Morgan Stanley
Morgan Stanley
$472.05
Hold
54.27%
Upside
Assigned
08/06/26
Morgan Stanley Keeps Their Hold Rating on Sarepta Therapeutics (SRPT)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AMRXAmneal Pharmaceuticals
DNTHDianthus Therapeutics
REPLReplimune Group
VSTMVerastem
OVIDOvid Therapeutics
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Sarepta Therapeutics

3 Months
Mitchell KapoorH.C. Wainwright
Success Rate
14/18 ratings generated profit
78%
Average Return
+10.17%
Copying Mitchell Kapoor's trades and holding each position for 3 Months would result in 77.78% of your transactions generating a profit, with an average return of +10.17% per trade.
1 Year
Mitchell KapoorH.C. Wainwright
Success Rate
13/18 ratings generated profit
72%
Average Return
+16.24%
Copying Mitchell Kapoor's trades and holding each position for 1 Year would result in 72.22% of your transactions generating a profit, with an average return of +16.24% per trade.
2 Years
Mitchell KapoorH.C. Wainwright
Success Rate
12/18 ratings generated profit
67%
Average Return
+13.81%
Copying Mitchell Kapoor's trades and holding each position for 2 Years would result in 66.67% of your transactions generating a profit, with an average return of +13.81% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

SRPT Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
8
6
5
6
8
Buy
1
2
1
1
0
Hold
12
13
13
15
17
Sell
2
4
4
6
5
Strong Sell
2
3
3
4
5
total
25
28
26
32
35
In the current month, SRPT has received 8 Buy Ratings, 17 Hold Ratings, and 10 Sell Ratings. SRPT average Analyst price target in the past 3 months is 406.60.
Each month's total comprises the sum of three months' worth of ratings.

SRPT Financial Forecast

SRPT Earnings Forecast

Next quarter’s earnings estimate for SRPT is $1.39 with a range of -$9.39 to $14.65. The previous quarter’s EPS was -$0.94. SRPT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year SRPT has Performed in-line its overall industry.
Next quarter’s earnings estimate for SRPT is $1.39 with a range of -$9.39 to $14.65. The previous quarter’s EPS was -$0.94. SRPT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year SRPT has Performed in-line its overall industry.

SRPT Sales Forecast

Next quarter’s sales forecast for SRPT is $6.62B with a range of $6.06B to $7.17B. The previous quarter’s sales results were $7.54B. SRPT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year SRPT has Performed in-line its overall industry.
Next quarter’s sales forecast for SRPT is $6.62B with a range of $6.06B to $7.17B. The previous quarter’s sales results were $7.54B. SRPT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year SRPT has Performed in-line its overall industry.

SRPT Stock Forecast FAQ

What is MX:SRPT’s average 12-month price target, according to analysts?
Based on analyst ratings, Sarepta Therapeutics’s 12-month average price target is 406.60.
    What is MX:SRPT’s upside potential, based on the analysts’ average price target?
    Sarepta Therapeutics has 32.87% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Sarepta Therapeutics a Buy, Sell or Hold?
          Sarepta Therapeutics has a consensus rating of Hold, which is based on 3 buy ratings, 10 hold ratings and 4 sell ratings.
            What is Sarepta Therapeutics’s share price target?
            The average share price target for Sarepta Therapeutics is 406.60. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is $717.52 ,and the lowest forecast is $94.41. The average share price target represents 32.87% Increase from the current price of $306.
              What do analysts say about Sarepta Therapeutics?
              Sarepta Therapeutics’s analyst rating consensus is a Hold. This is based on the ratings of 17 Wall Streets Analysts.
                How can I buy shares of Sarepta Therapeutics?
                To buy shares of MX:SRPT, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.